- Home
- GLTO vs SNGX Comparison
GLTO vs SNGX Comparison
Compare GLTO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- SNGX
- Stock Information
- Founded
- GLTO 2011
- SNGX 1987
- Country
- GLTO Denmark
- SNGX United States
- Employees
- GLTO N/A
- SNGX N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- SNGX Health Care
- Exchange
- GLTO Nasdaq
- SNGX Nasdaq
- Market Cap
- GLTO 6.5M
- SNGX 7.4M
- IPO Year
- GLTO 2020
- SNGX 1987
- Fundamental
- Price
- GLTO $5.50
- SNGX $2.40
- Analyst Decision
- GLTO Buy
- SNGX
- Analyst Count
- GLTO 1
- SNGX 0
- Target Price
- GLTO $10.00
- SNGX N/A
- AVG Volume (30 Days)
- GLTO 21.2K
- SNGX 621.9K
- Earning Date
- GLTO 03-07-2025
- SNGX 03-14-2025
- Dividend Yield
- GLTO N/A
- SNGX N/A
- EPS Growth
- GLTO N/A
- SNGX N/A
- EPS
- GLTO N/A
- SNGX N/A
- Revenue
- GLTO N/A
- SNGX $364,183.00
- Revenue This Year
- GLTO N/A
- SNGX N/A
- Revenue Next Year
- GLTO N/A
- SNGX $76.64
- P/E Ratio
- GLTO N/A
- SNGX N/A
- Revenue Growth
- GLTO N/A
- SNGX N/A
- 52 Week Low
- GLTO $4.40
- SNGX $1.83
- 52 Week High
- GLTO $23.50
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- GLTO 52.98
- SNGX 37.72
- Support Level
- GLTO $4.60
- SNGX $2.03
- Resistance Level
- GLTO $5.98
- SNGX $3.44
- Average True Range (ATR)
- GLTO 0.42
- SNGX 0.34
- MACD
- GLTO 0.08
- SNGX -0.06
- Stochastic Oscillator
- GLTO 65.22
- SNGX 26.06
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).